Skip to main navigation Skip to search Skip to main content

Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2

  • Pallav D. Patel
  • , Pengrong Yan
  • , Paul M. Seidler
  • , Hardik J. Patel
  • , Weilin Sun
  • , Chenghua Yang
  • , Nanette S. Que
  • , Tony Taldone
  • , Paola Finotti
  • , Ralph A. Stephani
  • , Daniel T. Gewirth
  • , Gabriela Chiosis
  • Memorial Sloan-Kettering Cancer Center
  • St. John's University
  • SUNY Buffalo
  • University of Padua

Research output: Contribution to journalArticlepeer-review

202 Scopus citations

Abstract

Although the Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy, the contribution of each paralog to the cancer phenotype is poorly understood. This is in large part because reagents to study paralog-specific functions in cancer cells have been unavailable. Here we combine compound library screening with structural and computational analyses to identify purine-based chemical tools that are specific for Hsp90 paralogs. We show that Grp94 selectivity is due to the insertion of these compounds into a new allosteric pocket. We use these tools to demonstrate that cancer cells use individual Hsp90 paralogs to regulate a client protein in a tumor-specific manner and in response to proteome alterations. Finally, we provide new mechanistic evidence explaining why selective Grp94 inhibition is particularly efficacious in certain breast cancers.

Original languageEnglish
Pages (from-to)677-684
Number of pages8
JournalNature Chemical Biology
Volume9
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Dive into the research topics of 'Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2'. Together they form a unique fingerprint.

Cite this